Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large drop in short interest during the month of August. As of August 31st, there was short interest totalling 75,700 shares, a drop of 6.8% from the August 15th total of 81,200 shares. Based on an average daily trading volume, of 151,400 shares, the short-interest ratio is presently 0.5 days. Currently, 1.3% of the company’s shares are sold short.

Hepion Pharmaceuticals Stock Performance

NASDAQ HEPA opened at $0.68 on Thursday. The stock has a market capitalization of $3.69 million, a P/E ratio of -0.07 and a beta of 1.85. Hepion Pharmaceuticals has a 52 week low of $0.55 and a 52 week high of $6.14. The stock has a fifty day moving average of $0.78 and a 200-day moving average of $1.32.

Hepion Pharmaceuticals (NASDAQ:HEPA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.68) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Hepion Pharmaceuticals stock. Armistice Capital LLC raised its holdings in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) by 5.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 418,000 shares of the company’s stock after acquiring an additional 20,393 shares during the quarter. Armistice Capital LLC owned about 9.63% of Hepion Pharmaceuticals worth $1,354,000 as of its most recent SEC filing. Institutional investors own 17.24% of the company’s stock.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.